Homepage | japcm

The European Joint Action on Personalised Cancer Medicine (JA PCM) brings together 29 European countries and 145 partner organisations to advance personalised cancer care across Europe. The 4 year project (2025-2029) aims to create a sustainable cross-border network to foster innovation, good practice, equity, and collaboration in personalised cancer care. The project is co-funded by the European Commission and has an overall budget of €31.6 million.

JA PCM ARMS

Prevention

Medicine

Follow-up

Highlights

Joint Action on Personalised Cancer Medicine officially launched in Brussels

The Joint Action on Personalised Cancer Medicine (JA PCM) was officially launched in Brussels, on 14 January 2026.

16 January, 2026

Read about @title

JA PCM Private Sector: Contribution Briefing & Initial Discussion

We kindly invite you for the meeting 'JA PCM Private Sector: Contribution Briefing & Initial Discussion'.

Webex

8 July, 2026

Read about @title

D1.1 JA PCM SPARC Synergy

This report outlines the first milestone in the structured collaboration between the Joint Action on Personalised Cancer Medicine (JA PCM) and the

31 January, 2026

Read about @title

See all Deliverables

Mapping the Adoption of Liquid Biopsy and Minimal Residual Disease Monitoring Across Europe

This report, produced under JA PCM WP10 (Tertiary prevention), maps the implementation of Liquid Biopsy (LB) and Minimal Residual Disease (MRD) monito

17 June, 2026

Read about @title

See all Project documents

Background

Stay updated with our newsletter

Subscribe to receive the latest updates and news on personalised medicine initiatives in Europe

Read the last newsletter